Abstract:Chimeric antigen receptors (CAR) are engineered fusion proteins constructed from antigen recognition, signaling, and costimulatory domains that can be expressed in cytotoxic T cells with the purpose of reprograming the T cells to specifically target tumor cells. CAR T-cell therapy uses gene transfer technology to reprogram a patient's own T cells to stably express CARs, thereby combining the specificity of an antibody with the potent cytotoxic and memory functions of a T cell. In early-phase clinical trials, CAR T cells targeting CD19 have resulted in sustained complete responses within a population of otherwise refractory patients with B-cell malignancies and, more specifically, have shown complete response rates of approximately 90% in patients with relapsed or refractory acute lymphoblastic leukemia. Given this clinical efficacy, preclinical development of CAR T-cell therapy for a number of cancer indications has been actively investigated, and the future of the CAR T-cell field is extensive and dynamic. Several approaches to increase the feasibility and safety of CAR T cells are currently being explored, including investigation into the mechanisms regulating the persistence of CAR T cells. In addition, numerous early-phase clinical trials are now investigating CAR T-cell therapy beyond targeting CD19, especially in solid tumors. Trials investigating combinations of CAR T cells with immune checkpoint blockade therapies are now beginning and results are eagerly awaited. This review evaluates several of the ongoing and future directions of CAR T-cell therapy.

New Progress of Adoptive Immunotherapy in the Treatment of Hematologic Malignancies Based on Chimeric Antigen Receptor T-cells: Reports from the 56th American Society of Hematology Annual Meeting

Chimeric Antigen Receptor Natural Killer Cells: a Promising Antitumor Immunotherapy

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

[Progress in Clinical Studies of Chimeric Antigen Receptor Engineered T Cells for Treatment of Childhood Cancer].

Novel Cellular Immunotherapies for Hematological Malignancies: Recent Updates from the 2021 ASH Annual Meeting

Recent Advances in Immunotherapy of Acute Leukemia Via Chimeric Antigen Receptor-Engineered T Cells

Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Gene Modified CAR-T Cellular Therapy for Hematologic Malignancies

The progress of CAR-T therapy in cancer and beyond

Current state of CAR-T therapy for T-cell malignancies

Current Status and Problems of Chimeric Antigen Receptor T Cell Immunotherapy in Treatment of Hematological Malignancies

Application of CAR-T Cell Immunotherapy in the Treatment of Hematological Malignancy

Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy

Recent advances in CAR T-cell therapy for lymphoma in China

Progress on CAR-T Cell Therapy for Hematological Malignancies

Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy

The application of CAR-T cell therapy in hematological malignancies: advantages and challenges

Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities

Recent advances in CAR-T cell engineering